TickerFacts.

Company research / NAMS

NewAmsterdam Pharma Co N.V. (NAMS)

Also trades as NAMSW. Every security a company lists rests on one set of financial statements, so these figures cover the whole company.

Build a valuation ↗↓ Download CSV

CIK 0001936258 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, NewAmsterdam Pharma Co N.V. reported revenue of $22.50M. Revenue fell 50.6% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $7.12M.

Key ratios (year ended 2025-12-31)

n/m
Operating margin
-905.7%
Net margin
-29.8%
Return on year-end equity
-50.6%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-02

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-31
Revenue$7.12M$22.50M$45.56M$14.09M$102.69Mn/a
R&D Expense$149.25M$141.83M$151.41M$159.42M$86.74M$28.97M
Operating Income-$244.41M-$225.68M-$176.29M-$182.97M-$3.56M-$34.98M
Depreciation & Amortization$244.0K$220.0K$113.0K$49.0K$9.0K$5.0K
EBITDA-$244.16M-$225.46M-$176.18M-$182.92M-$3.55M-$34.97M
Net Income-$259.50M-$203.82M-$241.60M-$176.94M-$22.63M-$41.78M
EPS (Diluted)n/a-$1.72-$2.56-$2.15-$1.19-$3.81
Total Assets$704.45M$769.28M$864.62M$347.10M$478.50Mn/a
Total Liabilities$73.03M$85.85M$107.12M$58.70M$48.43Mn/a
Shareholders' Equity$631.42M$683.43M$757.50M$288.39M$430.07M-$113.82M
Cash & Equivalents$424.15M$490.00M$771.74M$340.45Mn/an/a
Operating Cash Flow-$143.46M-$147.78M-$158.56M-$141.22M$10.66M-$29.51M
Capital Expenditures$260.0K$246.0K$672.0K$24.0K$221.0K$24.0K
Free Cash Flow-$143.72M-$148.03M-$159.24M-$141.24M$10.44M-$29.54M
Shares Outstanding117.65M114.40M108.06M82.47M81.56Mn/a
Weighted Average Diluted Sharesn/a118.42M94.36M82.16M18.97M10.98M
EPS (Basic)n/a-$1.72-$2.56-$2.15-$1.19-$3.81

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView